Abstract:It is well accepted that the balance of immunity between effector and regulatory T cells determines the outcome of autoimmune and chronic inflammatory diseases. Concerning the topic of ‘Regulatory and Effector T Cells’ as published in this issue of Journal of Molecular Cell Biology, several investigators have provided important new information. T-helper 1 (Th1) and Th2 cells represent the classical type of Th or effector cells. However, recent studies have also identified several new cell subsets of Th cells, including IL-9-producing T (Th9), IL-17-producing T (Th17), IL-22-producing T (Th22), and T follicular helper (Tfh) cells, extending the Th cell structure. Given their crucial role in the pathogenesis of autoimmune and inflammatory diseases, Th17 cells have received much attention. They mainly express IL-17A, but co-express IL-17B, IL-17E (IL-25), IL-17F, and IL-22. IL-26 is produced by human but not mouse Th17 cells. IL-17A is significantly more potent in initiating signaling and causing autoimmune responses than other cytokines produced by these cells. The differentiation of mouse Th17 cells needs the combination of IL-6 and transforming growth factor-beta (TGF-b) (Bettelli et al., 2006), although IL-6or TGF-b-independent pathways may also contribute to Th17 cell differentiation. The role of TGF-b in human Th17 cell differentiation is still controversial. Of note, the IL-21 and IL-1 signal pathways seem to be important in initiating Th17 cell development. IL-21 and IL-23 are also known to sustain and expand Th17 cells. Dr Ryffel’s group provides an updated account of the differentiation and function of Th17 cells, particularly during lung injury and inflammatory disease. They demonstrated that lung injury or allergen exposure leads to NLPR3 activation, with formation of the NLPR3 inflammasome complex and caspase-1 activation resulting in mature IL-1b, which may elicit IL-17 production. Traditionally, asthma is elicited by Th2 cells. It is still unclear whether Th17 cells work independent or together with Th2 cells in the development of asthma. They suggest that Th17 cells promote asthma through modulation of Th2 cells. In fact, IL-17E or IL-25, another IL-17 member, can induce Th2 cytokines and promote allergy. It is also possible that IL-17 regulates allergic responses independent of Th2 cells but Th2 cells promote asthma through Th17 cells since IL-4 does regulate IL-17 levels. It has been widely accepted that Tregs are critically involved in immune tolerance and homeostasis. Although this concept was suggested in early 1970s, it was resuscitated in 1990s when thymus-derived CD4+CD25+ cells were identified as natural Tregs (nTregs) (Sakaguchi et al., 1995). While Foxp3 has been identified as a unique marker and functional transcription factor for these cells, studies on Tregs have been greatly accelerated. As Treg frequency and functional alterations are associated with many autoimmune diseases, the manipulation of these cells provides a promising treatment possibility for autoimmune diseases. In addition, use of Tregs may be valuable in the prevention of graft rejection of organ transplantation and graft-versus-host disease (GVHD). Dr Bluestone’s group further provides information on the potential use of these cells in the clinic. They reported that by 2011, three clinical trials have been undertaken to test the safety of Treg therapy in GVHD, and all have demonstrated promising safety and efficacy profiles. Compelling evidence from animal models and human patients demonstrates that tolerance to allogeneic transplant can be achieved by reconditioning the immune system, so that troublesome global immunosuppression can be minimized or completely stopped. They emphasize that a sound trial design should harness the tolerogenic potential of Tregs while minimizing risks. One potential risk with Treg therapy is that these cells can purportedly exhibit some measure of plasticity. Since little is known about the appropriate doses of Tregs in humans, initial trials should be safety-centered evaluating effect of increasing

Treg-Resistant Cytotoxic CD4+ T Cells Dictate T Helper Cells in Their Vicinity: TH17 Skewing and Modulation of Proliferation

TGF-β–Induced Regulatory T Cells Directly Suppress B Cell Responses Through a Noncytotoxic Mechanism

Th Cells Promote Ctl Survival and Memory Via Acquired Pmhc-I and Endogenous Il-2 and Cd40l Signaling and by Modulating Apoptosis-Controlling Pathways

Emerging Topics and New Perspectives on Regulatory and Effector T Cells.

Excess generation and activation of naturally arising memory-phenotype CD4+ T lymphocytes are inhibited by regulatory T cells in steady state

TLR2 Stimulation Drives Human Naive and Effector Regulatory T Cells into a Th17-Like Phenotype with Reduced Suppressive Function

Steady-state, therapeutic, and helminth-induced IL-4 compromise protective CD8 T cell bystander activation

Acquisition of suppressive function by conventional T cells limits antitumor immunity upon Treg depletion

IL-2-deprivation and TGF-β are two non-redundant suppressor mechanisms of CD4+CD25+ regulatory T cell which jointly restrain CD4+CD25− cell activation

Cognate CD4+ T Cells Enhance CTL Survival and Memory Programming Via IL-2, CD40L and Acquired Pmhc-I Signaling (46.16)

One Way to Pathogenesis, Many Ways to Homeostasis

Convergence, plasticity, and tissue residence of regulatory T cell response via TCR repertoire prism

Treg-expressed CTLA-4 depletes CD80/CD86 by trogocytosis, releasing free PD-L1 on antigen-presenting cells

TCR-CD3 signal strength regulates plastic coexpression of IL-4 and IFN-γ in Tfh-like cells

Immune Homeostasis Enforced by Co-Localized Effector and Regulatory T Cells

B7-deficient autoreactive T cells are highly susceptible to suppression by CD4(+)CD25(+) regulatory T cells.

The Era of Cytotoxic CD4 T Cells

Treg plasticity and human diseases

CD4+ T cell memory is impaired by species-specific cytotoxic differentiation, but not by TCF-1 loss

Differentiation fate of a stem-like CD4 T cell controls immunity to cancer

Reduced suppressive effect of CD4+CD25high regulatory T cells on the T cell immune response against myelin oligodendrocyte glycoprotein in patients with multiple sclerosis